Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α
Open Access
- 4 October 2012
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1), 450
- https://doi.org/10.1186/1471-2407-12-450
Abstract
One-third of breast cancers display amplifications of the ERBB2 gene encoding the HER2 kinase receptor. Trastuzumab, a humanized antibody directed against an epitope on subdomain IV of the extracellular domain of HER2 is used for therapy of HER2-overexpressing mammary tumors. However, many tumors are either natively resistant or acquire resistance against Trastuzumab. Antibodies directed to different epitopes on the extracellular domain of HER2 are promising candidates for replacement or combinatorial therapy. For example, Pertuzumab that binds to subdomain II of HER2 extracellular domain and inhibits receptor dimerization is under clinical trial. Alternative antibodies directed to novel HER2 epitopes may serve as additional tools for breast cancer therapy. Our aim was to generate novel anti-HER2 monoclonal antibodies inhibiting the growth of breast cancer cells, either alone or in combination with tumor necrosis factor-α (TNF-α).Keywords
This publication has 47 references indexed in Scilit:
- Systematic exploration of synergistic drug pairsMolecular Systems Biology, 2011
- HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast CancerPLoS Biology, 2010
- The Ability to Generate Senescent Progeny as a Mechanism Underlying Breast Cancer Cell HeterogeneityPLOS ONE, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell LinesClinical Cancer Research, 2009
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- Life and death by death receptorsThe FASEB Journal, 2009
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003